Sanofi : The comeback of an upward trend can be anticipated
BUY
Repli_rebond
Target price hit
Entry price | Target | Stop-loss | Potential |
---|
€89.1 |
€94.4 |
€86.5 |
+5.95% |
---|
The timing from a technical point of view appears attractive to go long in shares of Sanofi and to anticipate a trend reversal.
Summary● Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
● According to Refinitiv, the company's ESG score for its industry is good.
Strengths● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
● The group's activity appears highly profitable thanks to its outperforming net margins.
● The company's attractive earnings multiples are brought to light by a P/E ratio at 18.16 for the current year.
● The company is one of the best yield companies with high dividend expectations.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The opinion of analysts covering the stock has improved over the past four months.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses● According to forecast, a sluggish sales growth is expected for the next fiscal years.
● The company's earnings growth outlook lacks momentum and is a weakness.
● The group usually releases earnings worse than estimated.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.